Skip to content
OpenCapital
Get started

Adaptive Biotechnologies ADPT Immune Medicine Business — Research And Development Expense

Other segment segments

Mrd Business
$9.23M+0.7%

Similar metrics at other companies

Johnson & Johnson logo
JNJInnovative Medicine — Research and development expense
$2.81B+10.4%
Becton, Dickinson and Company logo
BDXMedical — Research and development expense
$130.75M+17.0%
Disc Medicine logo
IRONInternal Research And Development — Research And Development Expense
$11.31M+67.6%
Innoviva, Inc. logo
INVAInternal Expenses — Research And Development Expense
$2.64M+95.9%
Nurix Therapeutics, Inc. logo
NRIXInternal research and development expenses — R&D
$57.07M+12.2%
Disc Medicine logo
IRONOther Research — Research And Development Expense
$2.17M+18.2%

Other financials

Income statement

See full
Revenue$70.9M+35.1%
Gross profit$52.2M+47.1%
Operating income-$19.2M+35.1%
Net income-$20.0M+32.9%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$77.6M+53.2%
Total debt$208.2M-5.6%
Total equity$216.3M+13.6%
Total assets$505.9M-1.0%

Cash flow

See full
Operating cash flow-$9.5M+66.5%
CapEx$796.0K-36.8%
Free cash flow-$10.3M+65.3%

Valuation

See full
Market cap$2.76B+93.6%
Enterprise value$2.89B+78.0%
P/S9.3×+1.8×

Profitability

See full
Gross margin75.3%+12.7pp
Operating margin-15.8%-7.0pp
Net margin-16.8%-7.3pp
FCF margin-10.5%-4.6pp

Returns & leverage

See full
Return on equity-24.4%-9.2pp
Debt / equity1×-0.2×
Current ratio3.4×+0.4×

Where this comes from

Reported directly by Adaptive Biotechnologies in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Adaptive Biotechnologies's immune medicine business — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Adaptive Biotechnologies's immune medicine business — research and development expense?
Adaptive Biotechnologies (ADPT) reported immune medicine business — research and development expense of $13.93M in Q1 2026.
How has Adaptive Biotechnologies's immune medicine business — research and development expense changed year-over-year?
Adaptive Biotechnologies's immune medicine business — research and development expense decreased by 3.8% year-over-year, from $14.49M to $13.93M.
What is the long-term trend for Adaptive Biotechnologies's immune medicine business — research and development expense?
Over 3 years (2022 to 2025), Adaptive Biotechnologies's immune medicine business — research and development expense has grown at a -20.2% compound annual growth rate (CAGR), from $109.99M to $55.86M.
What does immune medicine business — research and development expense mean?
This metric tracks the costs incurred by the Immune Medicine Business segment for research and development activities aimed at discovering and developing new immune-based diagnostic products. It reflects the company's investment in innovation and its commitment to advancing its clinical pipeline.